Fractional Flow Reserve Makes Inroads In Interventional Cardiology
Fractional flow reserve (FFR), a measurement of the severity of a coronary artery obstruction, has not yet reached mainstream use in the US, but that could soon change as interventional cardiologists face increased scrutiny about the “appropriateness” of their clinical treatment decisions. Part of that scrutiny will be driven by recent overstenting scandals, but cost-control measures are playing just much of a role in this shift. At the same time, ongoing advancements in FFR technology are helping to overcome barriers to use and could convince more physicians and hospitals to jump on the FFR bandwagon.
You may also be interested in...
Boston Scientific signed an agreement with the Japanese guidewire-maker Asahi Intecc to develop a fractional flow reserve wire that Boston seeks to launch as part of its first FFR system next year. Asahi will also provide components to upgrade Boston’s RotaWire atherectomy guidewire.
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.
Brief summaries of recent medtech market and industry developments. This month we cover results of St. Jude’s FAME II fractional flow reserve trial, a breakthrough technology for treating vascular occlusions, and analysis from START-UP magazine’s second annual Life Science Venture Capital Survey.